Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBionews2025-05-20T07:24:02+00:00May 20th, 2025|Endpoints News|
Retro Biosciences inks blood disorder deal as Sam Altman-backed biotech seeks $1B in fundsnews2025-05-20T04:01:33+00:00May 20th, 2025|Endpoints News|
BioMarin makes Phase 3 buy, paying $270M for rare disease outfit Inozymenews2025-05-16T15:08:49+00:00May 16th, 2025|Endpoints News|
Eli Lilly teams up with RNA editing biotech for hearing lossnews2025-05-15T17:30:49+00:00May 15th, 2025|Endpoints News|
Exclusive: Datavant will acquire Aetion, double life sciences teamnews2025-05-15T12:30:38+00:00May 15th, 2025|Endpoints News|
AbbVie doubles down on siRNA with $335M upfront bet on ADARxnews2025-05-14T13:00:05+00:00May 14th, 2025|Endpoints News|
GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hopenews2025-05-14T11:04:21+00:00May 14th, 2025|Endpoints News|
Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2Bnews2025-05-14T11:00:47+00:00May 14th, 2025|Endpoints News|
